Drugs / FAZ053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02936102 | Oct 2016 → Nov 2024 | soft tissue sarcoma, triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAZ053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936102 ↗ |
| Action | Inhibit | “By blocking the interaction between Programmed Death Ligand-1 (PD-L1) and its receptors, Programmed Death-1 (PD-1) and B7.1, FAZ053 inhibits the PD-L1 immune checkpoint” NCT02936102 ↗ |
| Route | Intravenous | “FAZ053 administered Intravenously (i.v.)” NCT02936102 ↗ |